Literature DB >> 19277417

Expression and prognostic significance of kallikrein-related peptidase 8 protein levels in advanced ovarian cancer by using automated quantitative analysis.

Panteleimon Kountourakis1, Amanda Psyrri, Andreas Scorilas, Sonia Markakis, Diane Kowalski, Robert L Camp, Eleftherios P Diamandis, Meletios A Dimopoulos.   

Abstract

Kallikrein-related peptidases, a subgroup of the serine protease enzyme family, are considered to be important prognostic biomarkers in cancer. In this study we sought to determine the prognostic value of kallikrein-related peptidase 8 (KLK8, hK8, KLK-8) in ovarian cancer using a novel method of compartmentalised in situ protein analysis. A tissue array composed of 150 advanced stage ovarian cancers, uniformly treated with surgical debulking followed by platinum-paclitaxel combination chemotherapy, was constructed. For the evaluation of kallikrein-related peptidase 8 protein expression, we used an immunofluorescence-based method of automated in situ quantitative protein analysis (AQUA). Mean follow-up time of the cohort was 34.35 months. One hundred twenty-six of 150 cases had sufficient tissue for AQUA analysis. There were significant correlations between tumour mask KLK8 protein expression levels and clinicopathological variables, including grade (p = 0.0011), residual disease (p = 0.0063) and clinical response to chemotherapy(p = 0.0346). In univariate survival analysis there was a significant correlation between KLK8 tumour mask expression and five years progression-free survival, meanwhile it was not associated with five-year overall survival (p = 0.0694). Specifically, low KLK8 expression correlated with better outcome (top vs. bottom quartile, p = 0.0319). In multivariate survival analysis, adjusting for well-characterised prognostic variables, tumour KLK8 expression level retained its prognostic significance for progression-free survival (95%CI: 0.341-1.027, p = 0.045). The possibility that KLK8 may be a suitable candidate as a diagnostic and prognostic marker warrants further investigation.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19277417

Source DB:  PubMed          Journal:  Thromb Haemost        ISSN: 0340-6245            Impact factor:   5.249


  7 in total

1.  Three dysregulated miRNAs control kallikrein 10 expression and cell proliferation in ovarian cancer.

Authors:  N M A White; T-F F Chow; S Mejia-Guerrero; M Diamandis; Y Rofael; H Faragalla; M Mankaruous; M Gabril; A Girgis; G M Yousef
Journal:  Br J Cancer       Date:  2010-03-30       Impact factor: 7.640

2.  Epigenetic remodeling regulates transcriptional changes between ovarian cancer and benign precursors.

Authors:  Kevin M Elias; Megan M Emori; Thomas Westerling; Henry Long; Anna Budina-Kolomets; Fugen Li; Emily MacDuffie; Michelle R Davis; Alexander Holman; Brian Lawney; Matthew L Freedman; John Quackenbush; Myles Brown; Ronny Drapkin
Journal:  JCI Insight       Date:  2016-08-18

3.  Clinical relevance of kallikrein-related peptidase 6 (KLK6) and 8 (KLK8) mRNA expression in advanced serous ovarian cancer.

Authors:  Nancy Ahmed; Julia Dorn; Rudolf Napieralski; Enken Drecoll; Matthias Kotzsch; Peter Goettig; Eman Zein; Stefanie Avril; Marion Kiechle; Eleftherios P Diamandis; Manfred Schmitt; Viktor Magdolen
Journal:  Biol Chem       Date:  2016-12-01       Impact factor: 3.915

4.  Optimizing molecular-targeted therapies in ovarian cancer: the renewed surge of interest in ovarian cancer biomarkers and cell signaling pathways.

Authors:  Donavon Hiss
Journal:  J Oncol       Date:  2012-02-06       Impact factor: 4.375

Review 5.  Involvement of Kallikrein-Related Peptidases in Normal and Pathologic Processes.

Authors:  Ana Carolina B Stefanini; Bianca Rodrigues da Cunha; Tiago Henrique; Eloiza H Tajara
Journal:  Dis Markers       Date:  2015-12-09       Impact factor: 3.434

6.  Increase of Serum Kallikrein-8 Level After Long-term Telbivudine Treatment.

Authors:  Haw-En Wang; Chih-Lang Lin; Tai-Long Pan; Chau-Ting Yeh
Journal:  In Vivo       Date:  2018 Jul-Aug       Impact factor: 2.155

7.  The diagnostic and prognostic value of serum human kallikrein-related peptidases 11 in non-small cell lung cancer.

Authors:  Chun-Hua Xu; Yu Zhang; Li-Ke Yu
Journal:  Tumour Biol       Date:  2014-02-09
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.